Hetero-oligomerization between the TNF receptor superfamily members CD40, Fas and TRAILR2 modulate CD40 signalling

Cristian R Smulski1,2,3, Marion Decossas1, Nella Chekkat1,6, Julien Beyrath1, Laure Willen2, Gilles Guichard4, Raquel Lorenzetti3, Marta Rizzi3,5, Hermann Eibel5, Pascal Schneider1,2,7 and Sylvie Fournel1,6,7

Robert Escarpit, Pessac Cedex F-33607, France and 5Department of Rheumatology and Clinical Immunology, University Medical Center Freiburg, Freiburg, Germany.

*Corresponding author: CR Smulski or P Schneider or S Fournel, Department of Biochemistry, University of Lausanne, Ch. des Boveresses 155, Epalinges CH-1066, Switzerland. Tel: +41 216925743; Fax: +41 216925705; E-mail: cristian.roberto.smulski@uniklinik-freiburg.de or pascal.schneider@unil.ch or s.fournel@unistra.fr

Abstract

TNF receptor superfamily members (TNFRSF) such as CD40, Fas and TRAIL receptor 2 (TRAILR2) participate to the adaptive immune response by eliciting survival, proliferation, differentiation and/or cell death signals. The balance between these signals determines the fate of the immune response. It was previously reported that these receptors are able to self-assemble in the absence of ligand through their extracellular regions. However, the role of this oligomerization is not well understood, and none of the proposed hypotheses take into account potential hetero-association of receptors. Using CD40 as bait in a flow cytometry Förster resonance energy transfer assay, TNFRSF members with known functions in B cells were probed for interactions. Both Fas and TRAILR2 associated with CD40. Immunoprecipitation experiments confirmed the interaction of CD40 with Fas at the endogenous levels in a BJAB B-cell lymphoma cell line deficient for TRAILR2. TRAILR2-expressing BJAB cells displayed a robust CD40–TRAILR2 interaction at the expense of the CD40–Fas interaction. The same results were obtained by proximity ligation assay, using TRAILR2-positive and -negative BJAB cells and primary human B cells. Expression of the extracellular domains of Fas or TRAILR2 with a glycolipid membrane anchor specifically reduced the intrinsic signalling pathway of CD40 in 293T cells. Conversely, BJAB cells lacking endogenous Fas or TRAILR2 showed an increased NF-κB response to CD40L. Finally, upregulation of TRAILR2 in primary human B cells correlated with reduced NF-κB activation and reduced proliferation in response to CD40L. Altogether, these data reveal that selective interactions between different TNFRSF members may modulate ligand-induced responses upstream signalling events.

Cell Death and Disease (2017) 8, e2601; doi:10.1038/cddis.2017.22; published online 9 February 2017

Germinal centres (GCs) are unique sites in peripheral lymphoid tissue where clonal selection of B-lymphocytes takes place in response to antigen stimulation. B-cell clonal selection results in differentiation of high-affinity B memory and antibody-secreting cells that permit an efficient secondary immune response.1–13 At the same time, GCs are known to be a major source of B-cell lymphomas including follicular and Burkit’s and also some diffuse large B-cell lymphoma.4,5 In the process of antibody affinity maturation that takes place in GCs, B-lymphocytes with low-affinity antigen receptor are eliminated by apoptosis, whereas those with higher affinity are selected and survive. The study of how apoptotic signals synchronize in the regulation of B-cell death in GC will contribute not only to a better understanding of the mechanisms supporting clonal selection of B-lymphocytes and high-affinity antibody production but also of lymphomagenesis or progression of B lymphomas of GC origin.

Several reports showed that Fas (CD95 or TNFRSF6), a pro-apoptotic TNF receptor (TNFR) superfamily member (TNFRSF), is directly involved in the clonal selection of GC B-lymphocytes.6–8 Other pro-apoptotic members of the same family, TRAIL receptors are also expressed in GC B-lymphocytes.9 In humans, there are four membrane-bound TRAIL receptors: two death receptors TRAIL receptor 1 (TRAILR1) and TRAILR2 (DR4 or TNFRSF10A and DR5 or TNFRSF10B, respectively) that mediate death signals and two decoy receptors TRAILR3 and TRAILR4 (DcR1 or TNFRSF10C and DcR2 or TNFRSF10D, respectively). Interestingly, Fas or TRAILR-mediated apoptosis is controlled or counterbalanced in GC cells by another TNFR superfamily member CD40 (TNFRSF5).10–13 It is conventionally accepted that CD40-induced protection against Fas or TRAILR-mediated apoptosis required NF-κB activation and upregulation of anti-apoptotic c-FLIP and Bcl-XL proteins.12,14–16 However, Benson et al.17 described a rapid CD40-mediated rescue from Fas-induced apoptosis that did not require NF-κB activation, was independent of de novo protein synthesis but was dependent upon active PI3K. Both previously described rescue mechanisms are ligand dependent, raising the
question whether the relative amount of receptors may impact directly on CD40 signalling in a ligand-independent way.

Several TNFRSF members are able to self-associate, in particular Fas, TRAILRs and CD40. We previously reported that CD40 can form non-covalent dimers in the absence of ligand, with an important contribution of the extracellular region to establish contacts. However, the potential for different TNFR family members to heteromerize has not been investigated. In this study, we identified selective interactions between CD40 and Fas, and between CD40 and TRAILR2. These heteromers also form at the endogenous level, and appear to be dynamic, driven by the preferential association of CD40 with TRAILR2 over Fas. The impact of heteromer formation on CD40 signalling was studied in cell lines and in primary human B cells, showing that they can negatively regulate CD40L-induced responses. Thus, heteromer formation between receptors with opposite functions could represent the most apical regulation of TNFRSF signalling.

**Results**

CD40 interacts with Fas and TRAILR2. The first evidence of CD40–Fas interaction was obtained by Förster resonance energy transfer (FRET) by flow cytometry. Fas was initially predicted to serve as a negative control for CD40–CD40 interaction, but yielded high FRET rates when it was co-transfected with CD40 (Figure 1a). Then, we tested the ability of CD40 to interact with other TNFRSF members important for B-cell function such as Fas, TRAILR1, TRAILR2, BCMA (TNFRSF17), BAFFR (BR3 or TNFRSF13C), TACI (TNFRSF13B) and the two unrelated receptors ErbB1 and ErbB2. No interaction could be detected with ErbB1, ErbB2, TRAILR1, TACI, BAFFR or BCMA. However, positive FRET responses were observed between CD40 and Fas and, to a lesser extent, between CD40 and TRAILR2 (Figure 1b). Ligand-independent associations of CD40 with itself, with Fas and with TRAILR2 were readily observed with constructs lacking the intracellular domain (ΔICD), indicating that the latter is not required for the observed homo- and hetero-oligomerizations (Figure 1c). No interaction was detected between Fas and TRAILR2. In summary, in transiently transfected 293T cells, CD40 interacts with Fas and TRAILR2 as detected by FRET and these interactions do not require the intracellular domains.

CD40 selectively interacts with TRAILR2 over Fas. In order to visualize these interactions in cells with endogenous expression levels, the CD40-positive and Fas-positive B-cell lymphoma cell line BJAB, with or without expression of TRAILR2, was used. Immunocytochemistry using antibodies against the ectodomains of CD40, Fas and TRAILR2 showed colocalization at the cell surface between CD40 and Fas in TRAILR2-negative BJAB cells. However, colocalization of CD40 and Fas was reduced in TRAILR2-positive BJAB when compared with TRAILR2-negative BJAB cells, despite similar Fas expression levels. Under the same conditions, colocalization of CD40 and TRAILR2 was detected in TRAILR2-positive BJAB cells (Figure 2, Supplementary Figures 1 and 2).

In line with these results, we found that CD40 and Fas co-immunoprecipitated in native membrane fractions of TRAILR2-negative BJAB cells, but that this interaction was strongly decreased in TRAILR2-positive cells, which instead showed co-immunoprecipitation of CD40 with TRAILR2 (Figure 3a). We next assessed these interactions by means of proximity ligation assays (PLAs), using the same primary antibodies used for immunocytochemistry. This technique allows the detection of interacting proteins at endogenous levels by connecting two protein-specific antibodies in close proximity with a complementary DNA probe that is annealed, amplified and visualized as a fluorescent spot. We found CD40-Fas spots on TRAILR2-negative BJAB cells and, as expected, only background CD40-TRAILR2 spots (Figures 3b and d). Interestingly, the number of CD40-Fas spots was significantly diminished in TRAILR2-positive BJAB cells, with a concomitant appearance of CD40-TRAILR2 spots (Figures 3c and d). These results, together with those of the co-immunoprecipitation experiments, indicate that these interactions can be found at the endogenous levels, and that CD40 selectively associates with TRAILR2 over Fas in BJAB cells.
CD40 with Fas or with TRAILR2 on activated human B-lymphocytes.

**Signalling-incompetent TRAILR2 or Fas decreases CD40 signalling.** We wanted to determine whether heteromerization of CD40 with TRAILR2 or Fas could modulate CD40-mediated NF-κB activation. However, Fas and TRAILR2 can also induce NF-κB activation and overexpression of Fas or TRAILR2 may indirectly impact on CD40 signals by inducing cell death. To rule out any direct contribution of Fas and TRAILR2 to NF-κB signalling, we used glycolipid-anchored constructs of these receptors lacking transmembrane and intracellular domains, and observed how these truncated receptors may change CD40-mediated signals. 293T cells were transfected with a constant amount of CD40 and CD40L together with increasing concentrations of CD40-GPI, TRAILR2-GPI, or Fas-GPI, and the NF-κB response was quantified using a luciferase reporter. As expected, increasing concentrations of CD40-GPI inhibited CD40 signalling, most probably by competition for CD40L binding. However, increasing concentrations of TRAILR2-GPI, which is unable to compete for CD40L binding, also inhibited CD40 signalling. A similar result was observed with higher amounts of Fas-GPI but no impact in CD40 signalling was observed upon expression of TACI-GPI (Figure 5a, left). None of these receptors (CD40-, Fas- or TRAILR2-GPI) had an effect on TACI-induced NF-κB response, indicating a specific impact on CD40 signalling (Figure 5a, right). The amount of transfected plasmid sufficient to inhibit 50% of CD40-induced NF-κB response was about 1.4 ng of CD40-GPI for 0.5 ng of full-length CD40. For TRAILR2-GPI, the amount of transfected plasmid sufficient to inhibit 50% of CD40-induced NF-κB response was about 11 ng per well. The differences between the strength of TRAILR2-GPI and Fas-GPI-mediated inhibition could be explained either by the endogenous expression of TRAILR2 in 293T cells, or by differences in the interaction affinities with CD40. The expression levels of TRAILR2-GPI remained relatively constant in the presence of either CD40 or TACI. Similarly, expression levels of CD40 and TACI were insensitive to the presence of TRAILR2-GPI (Figure 5b). In addition, TRAILR2-GPI did not impact on CD40–CD40L interaction, as determined by flow cytometry staining using Flag-tagged CD40 ligand (Figure 5b). Full-length CD40 and CD40-GPI showed similar expression levels on the cell surface when the same amount of plasmid was transfected (Figure 5c). Finally, GPI-anchored receptors were all expressed at similar levels (Figure 5c).
It was shown that the cysteine-rich domain 1 (CRD1) of Fas, TRAILR2, and CD40 mediates receptor self-assembly. In contrast to Fas-GPI, Fas-ΔCRD1-GPI did not interfere with CD40-mediated NF-κB activation, suggesting that the CRD1 of Fas may be involved in Fas-CD40 interaction (Figure 5d). No conclusive results could, however, be obtained with TRAILR2-ΔCRD1-GPI because this protein did not reach the cell surface, most probably due to folding problems similar to those reported when the CRD1 of CD40 was deleted or modified. Taken together, these results indicate that the extracellular domains of Fas and TRAILR2, but not that of TACI, negatively affect CD40L-mediated signalling in the absence of any direct contribution of Fas or TRAILR2 to the signal or detectable changes in the levels of CD40 expression or its ability to interact with CD40L.

Endogenous TRAILR2 or Fas modulate CD40 signalling.

To address the impact of endogenous Fas and TRAILR2 on CD40 signalling, we generated several clones of BJAB cells knocked-out for each of these receptors using the CRISPR/Cas9 system (Supplementary Figure 3). When tested for their ability to respond to CD40L, all Fas and TRAILR2 KO clones showed a significant, dose-dependent increase in CD40L-induced NF-κB response when compared with wild-type cells, whereas CD40 KO BJAB clones were, as expected, not responsive to CD40L stimulation (Figures 6a and b). These changes in the NF-κB response strongly suggest that CD40-Fas and CD40-TRAILR2 heteromerization regulates CD40 signalling, even if it is difficult to exclude that the absence of Fas or TRAILR2 may indirectly modulate this outcome.

In primary human B cells, the expression profile and the balance between CD40 and Fas signalling has been well described, however, the expression and function of TRAILR2 remains poorly explored in B-cell subsets. We found that primary human marginal zone B cells (MZ: CD27+ IgD+) express higher levels of TRAILR2 compared with switched memory cells (SM: CD27+ IgD-), whereas the expression of CD40 and Fas was similar in these two B-cell populations (Figures 6c, e and g). This difference was enhanced after
stimulation with CD40L+IL-21, with a peak of TRAILR2, Fas and CD40 expression at day 2 (Figures 6d, f and h). To study the impact of TRAILR2 expression on CD40 activation, we used CFSE-labelled cells to analyze the proliferative response of CD27+ B cells to CD40L stimulation. After 6 days of activation, TRAILR2 high cells did not proliferate as strongly as TRAILR2 low cells. A similar response was observed in four independent donors (Figures 6i-k). Phosphorylation of the NF-κB subunit p65/RelA was measured by flow cytometry as a marker of NF-κB activation in response to stimulation with CD40L. The percentage of phospho-p65-positive cells was significantly higher in switched memory cells (that have lower levels of TRAILR2) than in marginal zone B cells (that have higher levels of TRAILR2) (Figure 6l). Taken together, these results suggest that endogenous TRAILR2 may increase the threshold required to obtain CD40L-induced responses in cell lines and in primary human B cells.

Discussion

There are increasing evidences suggesting that TNFR superfamily members are organized in the cell membrane as ligand-independent oligomers rather than as individual receptors. Different receptors of the family have been described forming homo-dimers or -trimers, such as TNFR1 and 2, Fas, TRAIL receptors, CD40 and BAFFR. This pre-ligand assembly was reported in most cases to favour ligand binding and normal signalling. However, the potential heteromerization of TNFRs remains poorly explored and there are only three studies addressing this phenomenon, one between TRAILR2 and TRAILR4 and two others in the context of the central nervous system that describe the interaction of DR6 with p75NTR and DR6 with TROY. From the screening performed by flow cytometry FRET using CD40 as bait, we consistently found high FRET rates with Fas and to a lesser extent with TRAILR2. Other receptors important for B-cell survival and differentiation were negative in this screening. These interactions did not require the presence of the intracellular domain, which is in line with the fact that most of the TNFRSF–TNFRSF interactions described to date rely on the extracellular region of the receptors.

CD40-Fas and CD40-TRAILR2 interactions take place at the endogenous levels in the Burkitt B-cell lymphoma BJAB cell line expressing or not TRAILR2. Interestingly, the CD40–Fas
Figure 4  CD40 interacts with Fas and TRAILR2 in primary human B cells. (a) FACS expression profile of CD40 and Fas on primary human B cells non stimulated (NS), activated with PMA-ionomycin (PI) or activated with anti-BCR plus CD40L (BC) (left panels) together with a confocal image of the same cell type analyzed by PLA for CD40-Fas interaction (right panels) (one representative image out of three independent donors is shown). (b) Percentage of CD40-Fas double-positive cells in five different donors treated as described in panel a. (c) Mean and S.E.M. of the PLA assay for the three donors analyzed by PLA. Spot numbers were counted in positive cells in the focal plane. (d, e and f) Same as a–c, but for CD40-TRAILR2 interactions. The number of cells analyzed in the example is indicated on each image. Scale bars correspond to 5 μm. (g) HLA-DR and isotype control mean fluorescence intensity (MFI) and S.E.M. of five different human primary B cells samples that were either NS, activated with PI or activated with anti-BCR plus CD40L (BC). (h) Same as g, but for CD86 detection.
interaction was only detected in TRAILR2-negative BJAB cells despite similar expression levels of CD40 and Fas in both cell lines, indicating a possible competition between TRAILR2 and Fas for CD40 binding. This competition at the endogenous levels was evidenced by co-immunoprecipitations and by PLAs. However, the molecular basis for the observed selectivity in

**Figure 5** Heteromer formation with signalling-incompetent TRAILR2 or Fas has a negative impact on CD40 signalling. (a) NF-κB luciferase assay in 293T cells transiently transfected with 0.5 ng of CD40, 1 ng of CD40L (left panel) or with 0.5 ng of TACI, 1 ng of BAFF (right panel) and increasing amounts of GPI-anchored CD40, TRAILR2, Fas or TACI. One out of three independent assays with similar results is shown. (b) Flow cytometry analysis of TRAILR2-GPI, CD40 full-length and TACI full-length surface expression. (c) Left: surface expression levels of CD40 full-length, CD40-GPI and CD40 full-length in the presence of TRAILR2, detected by staining with Flag-CD40L. Right, surface expression levels of CD40-GPI and TRAILR2-GPI, detected by staining with an anti-TRAILR3 mAb recognizing the GPI-proximal region of the fusion receptor. MFI, mean of fluorescence intensity. (d) NF-κB luciferase assay in 293T cells transiently transfected with 0.5 ng of CD40, 1 ng of CD40L and increasing amounts of GPI-anchored Fas, Fas-ΔCRD1, CD40 and TACI. One out of two independent assays with similar results is shown. (e) Flow cytometry analysis of Fas and Fas-ΔCRD1 surface expression.
these interactions remains unclear. CD40 may have a higher affinity for TRAILR2 than for Fas, but these interactions may also be influenced by the relative abundance of each receptor on the cell surface. Finally, we cannot exclude that Fas or TRAILR2 may localize to specialized membrane microdomains in which CD40 could be recruited.

PLA studies confirmed that both CD40-Fas and CD40-TRAILR2 are close together in primary human B cells. In these

![Figure 6](image)

**Figure 6** Endogenous TRAILR2 or Fas modulate CD40 signalling. (a) NF-κB response of wild-type, Fas KO, TRAILR2 KO and CD40 KO BJAB cell lines induced by the indicated concentrations of Flag-ACRP-CD40L (mega-CD40L). One out of two independent experiments is shown (b). Average of the different clones and replicates of each KO cell line stimulated with 1 μg/ml of mega-CD40L. (c) Ex vivo expression profile of CD40 in marginal zone (MZ) and switched memory (SM) primary human B cells. (d) Expression profile of CD40 in MZ and SM along 6 days of CD40L+IL-21 stimulation. (e) Same as c and d, but for Fas expression. (g) Same as c and d, but for TRAILR2 expression. MZ B cells are gated as CD27+ IgD+ and SM B cells are gated as CD27+ IgD-. The mean and S.E.M. of six independent experiments is shown. (i) TRAILR2 expression in CD27+ B cells of one representative donor out of four tested after six days of CD40L+IL-21. (j) CFSE proliferation profile of TRAILR2 low CD27+ (grey histogram) and TRAILR2 high CD27+ (black line) primary human B cells of one representative donor out of four tested after six days of stimulation with CD40L+IL-21. (k) Average proliferative response for the four independent donors analyzed. (l) Flow cytometry analysis of phospho-p65 (RelA) after 5-min stimulation with CD40L. The figure shows five independent donors analyzed in duplicate.
experiments, CD40 was expressed in all conditions, and it was possible to preferentially induce Fas or TRAILR2 using different activation protocols. Cells in both stimulation conditions were not exactly comparable: Fas expression levels were different, and CD40 was engaged by ligand in one but not the other condition. Nonetheless, the results are fully compatible with a model in which CD40 preferentially interacts with TRAILR2 rather than with Fas. The preferred interaction between CD40 and TRAILR2 may thus be common to lymphoma cell lines and primary cells.

We have shown that expression of signalling-incompetent TRAILR2 or Fas, unable to interact with CD40L, decreased or sometimes totally abolished the ability of full-length CD40 to respond to CD40L with NF-κB activation. Under these circumstances, surface expression of CD40, and its ability to bind CD40L were unaffected, indicating that heteromers interfere with the signalling function by acting downstream of ligand binding, probably by interfering with formation of a functional signalling complex. Surface expression of full-length and GPI-anchored CD40 was similar, allowing comparisons to be performed. At the amount of transfected plasmid DNA sufficient for a 50% inhibition of CD40-induced NF-κB response, CD40-GPI was in a 3-fold excess over full-length CD40, and TRAILR2-GPI was in a 20-fold excess, which appears to be within a physiological range, especially when considering that the GPI fusion receptors may not be optimal for heteromer formation. In the case of TRAILR2-GPI, we carefully excluded the possibility of artefactual quenching of CD40L or CD40, suggesting that the observed effects are due to heteromer formation. It is tempting to speculate that the combined outcome of signalling via CD40 on the one hand, and TRAILR2 and Fas on the other hand, is not only regulated intracellularly by activation of pro- or anti-apoptotic signalling pathways, but also directly at the level of receptors whose relative expression levels may determine whether they can be activated or not. For several TNFRs, a pre-ligand assembly domain (PLAD) has been described that mediates homo- and hetero-interactions.\textsuperscript{18–20,23} The deletion of the CRD1 of Fas was sufficient to abrogate its inhibitory effect on CD40 signalling indicating that the PLAD of Fas may have a role in heteromer formation. However, TRAILR2 with a similar deletion did not reach the cell surface, precluding interpretation of whether TRAILR2 CRD1 is involved or not in heteromer interactions. The inhibitory impact of Fas and TRAILR2 on CD40 signalling has been confirmed in Fas and TRAILR2 KO BJAB cell lines, which showed increased responsiveness to CD40L.

In the biology of B cells, Fas and TRAILR2 are death receptors that trigger apoptosis of autoreactive and/or activated B cells.\textsuperscript{32,33} whereas CD40 is a potent NF-κB activator that provides activation and proliferation signals.\textsuperscript{34,35} However, the interplay between these three receptors is complicated and not fully understood. Several studies focused on the role of Fas during high-affinity B-cell selection in GC showing that Fas has an essential role in GC B-cell apoptosis both in vitro\textsuperscript{36} and in vivo.\textsuperscript{37} During B-cell maturation, somatic hypermutations are introduced in the variable regions of heavy and light chains of the BCR with the aim of generating antigen-specific B cells of higher affinity.\textsuperscript{37} A stringent selection mechanism takes place to ensure the survival of antigen-specific high-affinity B cells and the death of low-affinity or autoreactive B cells. GC B cells express CD40 and Fas and undergo FasL-mediated apoptosis, unless a survival signal is provided by BCR or CD40 engagement.\textsuperscript{38–41} The same type of data does not exist for TRAILR2, but it was shown ex vivo on primary human B cells that BCR and/or CD40L signals can rescue naïve B cells, but not memory B cells, from TRAIL-induced apoptosis.\textsuperscript{13} Together, these data suggest that signals transduced by Fas, TRAILR2 and CD40 are entangled to finely control the fate of B cells. In B-cell lymphomas, the relationship between CD40, Fas and TRAILRs appears even more complicated. As in normal GC B-lymphocytes, CD40 rescues apoptosis induced by Fas in low-grade B lymphoma, but CD40 sensitizes Burkitt lymphoma B cells to Fas-induced apoptosis.\textsuperscript{42–44} In a similar way, CD40 triggering protects Burkitt lymphoma\textsuperscript{13} and follicular lymphoma,\textsuperscript{45,46} but sensitizes chronic lymphocytic leukaemia B cells to apoptosis induced by TRAIL.\textsuperscript{57} The measure of TRAILR2 expression revealed that expression of this receptor is increased in marginal zone compared with switched memory B cells and that this difference is maintained upon CD40L+IL-21 stimulation. \textit{Our in vitro} data would be in line with the notion that TRAILR2 negatively regulates CD40L effects, as its expression inversely correlated with CD40L-induced proliferation in primary human B cells. Accordingly, CD40L-induced phosphorylation of p65 (RelA) inversely correlated with TRAILR2 expression in primary human B cells. This was true when analyzing percentage of phospho-p65-positive cells, but was not as marked when analyzing mean fluorescence intensities, suggesting that TRAILR2 may increase the threshold of CD40L stimulation required to activate CD40, but may not modify signalling once CD40 has been activated.

At this stage of the study, experiments performed in primary cells correlate TRAILR2 expression with lower responses to CD40L (NF-κB and proliferation). It would be interesting in the future to knock-out TRAILR2 from primary human B cells and test whether this increases responsiveness to CD40L, or to produce a mouse model with inducible knock-out of TRAILR. Mice, however, display significant differences with human in their array of TRAIL receptors,\textsuperscript{48} and it would be necessary to test first whether TRAILR–CD40 interactions also take place in mice.

In conclusion, our results reveal that ligand-independent heteromer formation between different TNFRSF members may be involved in the modulation of very early steps of activation, upstream of their signalling pathways.

Materials and Methods

Cell lines. BJAB cells expressing TRAILR2 or not were grown in RPMI 1640 medium (Lonza, Verviers, Belgium) supplemented with 10% foetal calf serum and 5 μg/ml each of penicillin and streptomycin. HEK 293T cells were grown in DMEM medium (Gibco, Carlsbad, CA, USA) supplemented with 10% foetal calf serum. BJAB Fas KO, BJAB TRAILR2 KO and BJAB CD40 KO were generated by lentiviral transduction using CRISPR/Cas9 expression vectors carrying the corresponding gRNAs (Supplementary Table S1), according to Shalem \textit{et al.}\textsuperscript{39}

Antibodies and TNF ligands. Western blot: anti-CD40 S-17 (Santa Cruz Biotechnology, Dallas, TX, USA), anti-Fas (ZB4) (Abcam, Cambridge, UK), anti-DR5 (Milestone, Billerica, MA, USA). Immunoprecipitations: anti-CD40 C20 agarose conjugate (Santa Cruz Biotechnology), anti-Fas (C20) (Santa Cruz Biotechnology), anti-DR5 D4E9 (Cell Signalling, Danvers, MA, USA). Flow cytometry: anti-CD40-FITC and –PE-Cy5 (5C3), anti-Fas-PE (DX2), anti-MHC-II-FITC (Tü 39), anti-CD86-
Expression plasmids. See Supplementary Table 1.

Förster resonance energy transfer. Experiments were performed using a LSM 700 flow cytometer instrument (BD Biosciences), EYFP signal was recorded using the 488 nm laser with a 530/50 filter, ECFP signal was recorded using the 405 nm laser with a 530/30 filter, ECFP signal was recorded using the 405 nm laser with a 530/30 filter, and ECFP signal was recorded using the 405 nm laser with a 530/30 filter.

Luciferase reporter assay. HEK293T cells were cultured in 96-well plates at 3 x 10^5 cells/ml in 100 μl. After 24 h, cells were transfected with a mix of vectors containing: EGFP (transfection efficiency control) (7 ng), control Renilla vector (7 ng), NF-κB firefly luciferase reporter vector (7 ng), CD40 (0.5 ng), CD40L (1 ng) and increasing concentrations of GPI-anchored CD40, TRAILR2, Fas or TACI (0 to 3 ng) (70 ng per well total DNA), using Polyfect transfection reagent (Qiagen, Hilden, Germany). After 24 h, cells were lysed and expression of firefly and renilla luciferases was detected with the dual luciferase assay detection kit (Promega, Madison, MI, USA).

Statistical analysis. FRET experiments were analyzed using unpaired t-test, and when multiple receptors where compared using one-way ANOVA with Tukey's post-test. PLA on BJAB cells was analyzed using unpaired t-test. PLA on B cells was analyzed using one-way ANOVA (non parametric Kruskal–Wallis test) with Dunn post-test. NF-κB luciferase reporter assay in BJAB cells was analyzed using one-way ANOVA with Tukey post-test. Differences between marginal zone and switched memory B cells were analyzed using unpaired t-test. All analyses were performed using GraphPad Prism version 5.00 for Windows, GraphPad Software, San Diego, CA USA; www.graphpad.com.

Conflict of Interest

The authors declare no conflict of interest.

Acknowledgements. We thank Andrew Thorburn for providing BJAB TRAILR2/TRAILR2* cell lines, Marie-Christine Rio and Fabien Alpy for kindly providing ErbB-EYFP constructs, Fabio Martonin (University of Lausanne) for valuable advice regarding the generation of receptor-deficient BJAB cells and Léa Zaffalon (University of Lausanne) for help in the construction of lentiviral vectors. We thank Sylviane Muller (UPR 3572 Strasbourg, France), the GDR2588 and the French Network for Microscopy (RTMfn) for scientific discussions and the microscopy facility platform of Strasbourg Esplanade for the use of the confocal microscope. This work was supported by grants from Agence Nationale de la Recherche (ANR-08-PCV1/0034-01) (to SF and GG) and the Swiss National Science Foundation (31003A-138065 to PS). NC was granted by the French Network for Microscopy (RTMfn) for scientific discussions and the microscopy facility platform of Strasbourg Esplanade for the use of the confocal microscope. The work was supported by grants from Agence Nationale de la Recherche (ANR-08-PCV1/0034-01) (to SF and GG) and the Swiss National Science Foundation (31003A-138065 to PS). NC was granted by the French ‘Ministère de la recherche’; LR was supported by CAPES Foundation, Ministry of Education of Brazil, Brasilia/DF 70040-020, Brazil (2810/13-2); MR by the DFG through SFB1160 (project 04) and HE by the DFG through TRR130 (project 06).
15. Kreuz S, Siegmund D, Scheurich P, Wajant H. NF-κB.
16. Lee HH, Dadgostar H, Cheng Q, Shu J, Cheng G. NF-kappaB-mediated up-regulation of et al.
17. Benson RJ, Hostager BS, Bishop GA. Rapid CD40-mediated rescue from CD95-induced et al.
18. Siegel RM, Frederiksen JK, Zacharias DA, Chan FK, Johnson M, Lynch D et al.
19. Hao Z, Duncan GS, Seagal J, Su YW, Hong C, Haight J et al. A common single nucleotide et al.
20. van Eijk M, Defrance T, Hennino A, de Groot C. Death-receptor contribution to the germinal-center et al.
21. Takahashi Y, Ohta H, Takemori T. Fas is required for clonal selection in germinal centers and the subsequent establishment of the memory B cell repertoire. Immunity 2001; 14: 181–192.
22. van Eijl M, Defrance T, Hemmink A, de Groot C. Death-receptor contribution to the germinal-center et al.
23. Greil R, Anether G, Johrer K, Tinhofer I. Tracking death dealing by Fas and TRAIL in et al.
24. Takahashi Y, Ohta H, Takemori T. Fas is required for clonal selection in germinal centers and the subsequent establishment of the memory B cell repertoire. Immunity 2001; 155: 2329–3337.
25. Mtiraf S, Naresh KN, Redkar AA, Nadkarni JJ. CD40-ligation-mediated protection from et al.
26. Benson RJ, Hostager BS, Bishop GA. Rapid CD40-mediated rescue from CD95-induced apoptosis. Blood 2003; 102: 3270–3279.
27. Guerreo-Cacao AO, Levitiskaja Y, Levitiskiy V. Cell receptor triggering sensitizes human B cells to TRAIL-induced apoptosis. J Leukocyte Biol 2010; 88: 937–945.
28. Travers M, Ame-Thomas P, Panguaut C, Moriot A, Micheau O, SEMA et al. CD40 ligand protects from TRAIL-induced apoptosis in follicular lymphomas through NF-κB activation and up-regulation of c-FLIP and Bcl-xL. Journal of Immunology 2008; 181: 1001–1011.
29. Kreuz S, Siegmund D, Scheurich P, Wajant H. NF-κB induces up-regulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling. Mol Cell Biol 2011; 21: 3984–3997.
30. Lee HH, Dogdostar H, Cheng Q, Shu J, Cheng G. NF-kappaB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes. J Immunol 1998; 166: 1014–1021.
31. Zaccaroni F, Papa S, Algeciras-Schimich M, Alvarez K, Melis T, Bubici C et al. Gadd45 beta mediates the protective effects of CD40 costimulation against Fas-induced apoptosis. Blood 2003; 102: 3270–3279.
32. Travers M, Ame-Thomas P, Panguaut C, Moriot A, Micheau O, SEMA et al. CD40 ligand protects from TRAIL-induced apoptosis in follicular lymphomas through NF-κB activation and up-regulation of c-FLIP and Bcl-xL. Journal of Immunology 2008; 181: 1001–1011.
33. Ursini-Siegel J, Zhang W, Altmeyer A, Hatada EN, Do RK, Yagita H et al. Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, Noelle RJ. Molecular mechanisms and function of CD40/CD40L engagement in the immune system. Immunol Rev 2009; 229: 152–172.
34. Ravkilde RD, Zhao H, Chatham WW, Zhou T, Carter RH. B lymphocytes are resistant to death receptor 5-induced apoptosis. Clin Immunol 2011; 139: 21–31.
35. Cleary AM, Fortune SM, Yellin MJ, Chess L, Lederman S. Opposing roles of CD95 (Fas/APO-1) and CD40 in the death and rescue of human low density tansillar B cells. J Immunol 1995; 155: 3229–3237.
36. Mootz HG, Naresh KN, Redkar AA, Nadkarni JJ. CD40-ligation-mediated protection from et al.
37. Victora GD, Nussenzweig CM. Germinal centers. Annu Rev Immunol 2012; 30: 429–457.
38. Wang J, Watanabe T. Expression and function of Fas during differentiation and activation of B-cells. J Exp Med 1999; 18: 367–379.
39. Rothstein TL, Zhong X, Schram BR, Negri RS, Donohoe TJ, Cabral DB et al. Receptor-specific regulation of B-cell susceptibility to Fas-mediated apoptosis and a novel Fas apoptosis inhibitor molecule. Immunol Rev 2000; 176: 116–133.
40. Mizuto T, Zhong X, Rothstein TL. Fas-induced apoptosis in B cells. Apoptosis 2003; 8: 451–4604.
41. Koopman G, Keimhen LM, Lindher Z, Zhou DF, de Groot C, Pals ST. Germinal center B cells rescued from apoptosis by CD40 ligation or attachment to follicular dendritic cells, but not by engagement of surface immunoglobulin or adhesion receptors, become resistant to CD95-induced apoptosis. Eur J Immunol 1997; 27: 1–7.
42. Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, Noelle RJ. Molecular mechanisms and function of CD40/CD40L engagement in the immune system. Immunol Rev 2009; 229: 152–172.
43. Wang J, Watanabe T. Expression and function of Fas during differentiation and activation of B-cells. J Exp Med 1999; 18: 367–379.
44. Rothstein TL, Zhong X, Schram BR, Negri RS, Donohoe TJ, Cabral DB et al. Receptor-specific regulation of B-cell susceptibility to Fas-mediated apoptosis and a novel Fas apoptosis inhibitor molecule. Immunol Rev 2000; 176: 116–133.
45. Mizuto T, Zhong X, Rothstein TL. Fas-induced apoptosis in B cells. Apoptosis 2003; 8: 451–4604.
46. Travers M, Ame-Thomas P, Panguaut C, Moriot A, Micheau O, Semma et al. CD40 ligand protects from TRAIL-induced apoptosis in follicular lymphomas through NF-κB activation and up-regulation of c-FLIP and Bcl-xL. J Immunol 2008; 181: 1001–1011.
47. Fas adaptor proteins: the \( R a c \) and \( R a c \) proteins. Nature 2000; 408: 573–577.
48. Travers M, Ame-Thomas P, Panguaut C, Moriot A, Micheau O, Semma et al. CD40 ligand protects from TRAIL-induced apoptosis in follicular lymphomas through NF-κB activation and up-regulation of c-FLIP and Bcl-xL. J Immunol 2008; 181: 1001–1011.
49. Nakatani Y, Takeichi M. The effect of tumor necrosis factor receptor family-related death domain (FADD) on the activation of the NF-κB pathway. J Biol Chem 2001; 276: 13150–13153.
50. Nakatani Y, Takeichi M. The effect of tumor necrosis factor receptor family-related death domain (FADD) on the activation of the NF-κB pathway. J Biol Chem 2001; 276: 13150–13153.
51. Nakatani Y, Takeichi M. The effect of tumor necrosis factor receptor family-related death domain (FADD) on the activation of the NF-κB pathway. J Biol Chem 2001; 276: 13150–13153.